24/7 Market News Snapshot 19 December, 2024 – Omeros Corporation (NASDAQ:OMER)

December 19, 2024

DENVER, Colo., 19 December, 2024 (247marketnews.com) – (NASDAQ:OMER) are discussed in this article.
Omeros Corporation (OMER) has recently captured significant attention in the financial markets, with shares soaring approximately 67.72% to trade at $12.51, up from a previous close of $7.46. This sharp increase in stock price has been accompanied by a trading volume of 1.36 million shares, reflecting a surge in investor interest. The company is experiencing notable bullish momentum, prompting investors to closely monitor pivotal support and resistance levels to gauge future performance.

Concurrently, Omeros has achieved a significant milestone regarding its innovative monoclonal antibody, narsoplimab, which targets the lectin pathway of complement. Recent independent statistical analysis results from the OMS721-TMA-001 trial reveal that narsoplimab has yielded a clinically meaningful and statistically significant improvement in overall survival rates among patients suffering from hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The analysis, which compared 28 treated TA-TMA patients against over 100 individuals from a comprehensive external control registry, reported a hazard ratio of 0.32 and an extraordinary p-value of less than 0.00001.

Dr. Gregory A. Demopulos, Chairman and CEO of Omeros, emphasized the importance of these findings, stating, “These results represent a major advance in our understanding and approach to treating TA-TMA.” In light of the significant unmet medical need in this area, Omeros plans to promptly resubmit the Biologics License Application (BLA) for narsoplimab to the FDA. The findings have garnered support from independent experts, who have underscored the necessity for effective treatment options for TA-TMA. Omeros is dedicated to accelerating the development of narsoplimab to enhance patient care in this critical therapeutic landscape.

Related news for (OMER)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.